key: cord-1002457-ke0g4wt3 authors: Fragoso, Gladis; Sciutto, Edda title: GK1: An Alternative Treatment to Control the Respiratory Complications During COVID19 date: 2020-11-02 journal: Arch Med Res DOI: 10.1016/j.arcmed.2020.10.019 sha: cd9bf6b9dfdd2fac4fb8c7f4ab9023395cf70200 doc_id: 1002457 cord_uid: ke0g4wt3 nan Considering the emergence of the global Covid-19 pandemic and the current lack of vaccines and therapies partially effective to treat severe cases, we would like to consider the use of GK-1, a novel peptide that we have found to enhance and immunomodulate the immune response to an antigenic challenge of different sources. We summarize below the most relevant points of basic biomedical knowledge about this GK-1 peptide that underlie our proposal. GK-1 is a synthetic peptide of 18 amino acids (GYYYPSDPNTFYAPPYSA) identified by our research group in the Taenia crassiceps cestode that is part of the effective synthetic vaccine against Taenia solium porcine cysticercosis (1). Unexpectedly, GK-1 induced high level of protection against experimental cysticercosis in vaccinated mice without the requirement of any adjuvant (2). The GK-1 co-immunization with the human influenza vaccine increased the titer of IgG specific antibodies and the specific cellular immunity and increased the protection in mice (3, 4) . Indeed, it was observed that GK-1 promotes the infiltration of mononuclear cells (lymphocytes and macrophages) into the lung parenchyma a few days after influenza infection in mice immunized together with the influenza vaccine; a response that could be related to the resolution capacity of the lung infection (3) . The increase in the vaccination efficiency seem to lie in the ability of GK-1 to promote in dendritic cells (5) and macrophages (6) Besides, GK-1 significantly increases life expectancy, reduces tumor growth in mice with melanoma and breast cancer (6,7) and the number of macrometastasis in lung in mice with breast cancer. These effects could be probably occurred through the downregulation of the PD-1/PD-L1 pathway and the increased activation and cytotoxic activity of CD8 + lymphocytes in both murine models (8) . Stability studies reveal that GK-1 is stable over a wide range of temperatures and pH and lyophilized can be kept at room temperature (9) and pre-clinical studies demonstrated that is harmless and not mutagenic (10) . The effect of GK-1 on the possible potentiation of the specific immune response in COVID-19 is supported by the observation that co-immunization of influenza vaccine with GK-1 increased the specific humoral and cellular immune response against the influenza virus (3, 4) . The ability of GK-1 to activate macrophages and dendritic cells optimizing their antigenic presentation (5,6) could underlie the immunoenhancing effect. Moreover, GK-1 also exhibited immunomodulatory properties, either by promoting the induction of a M1 temporal phenotype that later shifted to a regulatory M2 phenotype that could help in reducing the cytokine storm in COVID-19. Considering the findings that support the ability of GK-1 to boost immunity in different experimental circumstances and different species, as well as its safety, we would like you to consider the use of this new biological tool as a possible immunomodulator against Covid-19 that are under development or as an immunopotentiator to favor the resolution of Covid-19 respiratory complications. Our team are keen to collaborate with any efforts to evaluate, under strict monitoring protocols, the potential of J o u r n a l P r e -p r o o f Development of the S3Pvac vaccine against porcine Taenia solium cysticercosis: a historical review Heterologous prime-boost oral immunization with GK-1 peptide from Taenia crassiceps cysticerci induces protective immunity A novel synthetic adjuvant effectively enhances the immunogenicity of the influenza vaccine Towards identification of the mechanisms of action of parasite-derived peptide GK1 on the immunogenicity of an influenza vaccine Helminth-derived peptide GK-1 induces Myd88-dependent pro-inflammatory signaling events in bone marrow-derived antigen-presenting cells Impact of the GK-1 adjuvant on peritoneal macrophages gene expression and phagocytosis GK-1 peptide reduces tumor growth, decreases metastatic burden, and increases survival in a murine breast cancer model The synthetic parasite-derived peptide GK1 increases survival in a preclinical mouse melanoma model The helminth-derived peptide GK-1 induces an anti-tumoral CD8 T cell response associated with downregulation of the PD-1/PD-L1 pathway High stability of the immunomodulatory GK-1 synthetic peptide measured by a reversed phase high-performance liquid chromatography method Preclinical evidences of safety of a new synthetic adjuvant to formulate with the influenza human vaccine: absence of subchronic toxicity and mutagenicity